Premium
Azide Oximes and 1‐Hydroxytetrazoles
Author(s) -
Rehse Klaus,
Brehme Franziska
Publication year - 2000
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/1521-4184(20006)333:6<157::aid-ardp157>3.0.co;2-c
Subject(s) - antithrombotic , azide , chemistry , nitric oxide , in vitro , oxime , thrombus , ic50 , stereochemistry , pharmacology , biochemistry , organic chemistry , surgery , medicine
Eleven azide oximes were prepared and tested for their antiplatelet (in vitro), antithrombotic, and blood pressure lowering activities. Nine of them inhibited the aggregation of blood platelets (Born test, inducer collagen) with IC 50 values between 10 and 50 μM. The most active compounds i.e. azido‐4‐nitrophenylbenzaldoxime ( 2h ) had an IC 50 = 2 μM. Nine azide oximes exhibited significant antithrombotic properties. The most active compounds were 2h and 2c (azido‐4‐methylphenylbenzaldoxime) with an inhibition of thrombus formation above 20% in arterioles after a single p.o. dose of 60 mg/kg. Both compounds lowered the blood pressure in spontaneously hypertensive rats by 11% ( 2h ) or 5% ( 2c ), respectively. Seven azide oximes were rearranged to the title tetrazololes which however showed smaller antithrombotic effects. In separate in vitro experiments at 37 °C it could be demonstrated that azide oximes release nitric oxide (conversion rate ∼ 10% · h ‐1 ) and nitrosohydrogen (conversion rate ∼ 2% · h ‐1 ). This makes it appear probable that the above effects are mediated by these molecules.